Overbrook Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $11.2M | Sell |
42,968
-1,311
| -3% | -$336K | 1.75% | 18 |
|
|
2026
Q2 | $11.1M | Sell |
44,279
-10,865
| -20% | -$2.34M | 1.68% | 21 |
|
|
2026
Q1 | $12M | Buy |
55,144
+13,085
| +31% | +$2.9M | 2.27% | 17 |
|
|
2025
Q4 | $9.6M | Buy |
+42,059
| New | +$9.6M | 1.66% | 21 |
|
|
2020
Q1 | – | Sell |
-9,570
| Closed | -$847K | – | 70 |
|
|
2019
Q4 | $847K | Buy |
9,570
+500
| +6% | +$41.5K | 0.25% | 46 |
|
|
2019
Q3 | $687K | Hold |
9,070
| – | – | 0.17% | 50 |
|
|
2019
Q2 | $660K | Sell |
9,070
-26,922
| -75% | -$2.12M | 0.14% | 50 |
|
|
2019
Q1 | $2.9M | Hold |
35,992
| – | – | 0.62% | 31 |
|
|
2018
Q4 | $3.32M | Sell |
35,992
-23
| -0.1% | -$2.02K | 0.77% | 29 |
|
|
2018
Q3 | $3.41M | Hold |
36,015
| – | – | 0.65% | 35 |
|
|
2018
Q2 | $3.34M | Sell |
36,015
-449
| -1% | -$43.8K | 0.63% | 31 |
|
|
2018
Q1 | $3.45M | Sell |
36,464
-352
| -1% | -$38.7K | 0.71% | 30 |
|
|
2017
Q4 | $3.56M | Buy |
36,816
+163
| +0.4% | +$15.4K | 0.72% | 30 |
|
|
2017
Q3 | $3.26M | Sell |
36,653
-8,014
| -18% | -$610K | 0.74% | 28 |
|
|
2017
Q2 | $3.24M | Sell |
44,667
-8,981
| -17% | -$604K | 0.7% | 31 |
|
|
2017
Q1 | $3.5M | Sell |
53,648
-3,270
| -6% | -$206K | 0.76% | 30 |
|
|
2016
Q4 | $3.56M | Sell |
56,918
-720
| -1% | -$43.9K | 0.78% | 29 |
|
|
2016
Q3 | $3.64M | Sell |
57,638
-5,110
| -8% | -$331K | 0.84% | 28 |
|
|
2016
Q2 | $3.88M | Sell |
62,748
-525
| -0.8% | -$32K | 0.81% | 28 |
|
|
2016
Q1 | $3.61M | Sell |
63,273
-150
| -0.2% | -$8.36K | 0.78% | 29 |
|
|
2015
Q4 | $3.76M | Sell |
63,423
-265
| -0.4% | -$15.3K | 0.66% | 26 |
|
|
2015
Q3 | $3.46M | Buy |
63,688
+90
| +0.1% | +$5.86K | 0.53% | 31 |
|
|
2015
Q2 | $4.27M | Buy |
63,598
+1,623
| +3% | +$106K | 0.65% | 30 |
|
|
2015
Q1 | $3.63M | Sell |
61,975
-1,758
| -3% | -$106K | 0.59% | 33 |
|
|
2014
Q4 | $4.17M | Buy |
63,733
+1,180
| +2% | +$74.4K | 0.84% | 23 |
|
|
2014
Q3 | $3.61M | Sell |
62,553
-450
| -0.7% | -$25K | 0.57% | 34 |
|
|
2014
Q2 | $3.56M | Sell |
63,003
-2,090
| -3% | -$110K | 0.63% | 36 |
|
|
2014
Q1 | $3.35M | Sell |
65,093
-3,604
| -5% | -$182K | 0.64% | 38 |
|
|
2013
Q4 | $3.63M | Sell |
68,697
-4,745
| -6% | -$233K | 0.69% | 37 |
|
|
2013
Q3 | $3.28M | Buy |
73,442
+1,020
| +1% | +$45.2K | 0.76% | 39 |
|
|
2013
Q2 | $2.99M | Buy |
+72,422
| New | +$3.17M | 0.72% | 38 |
|
Other funds holding ABBV
Overbrook Management's ABBV Position: Q3 2026 in Review
Overbrook Management reduced its AbbVie (ABBV) stake by 3% in Q3 2026, selling an estimated $336K and leaving 42,968 shares worth $11.2M. The position accounts for 1.75% of the portfolio, ranked #18.
Overbrook Management first reported a position in ABBV in Q2 2013 and has held it in 31 quarters since. The position peaked at $12M in Q1 2026. 3,830 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.
- Overbrook Management held 42,968 shares of AbbVie worth $11.2M as of Q3 2026.
- Overbrook Management sold 1,311 AbbVie shares in Q3 2026, an estimated $336K.
- AbbVie made up 1.75% of Overbrook Management's portfolio in Q3 2026, its #18 holding.
- Overbrook Management first reported a position in AbbVie in Q2 2013 and has held it in 31 quarters since.
- Overbrook Management's AbbVie position peaked at $12M in Q1 2026.
- 3,830 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.
Based on Overbrook Management's 13F filing for Q3 2026, filed 8 Oct 2026.